| Karen Jean Laderach, OTR/L | |
|
2550 S State Route 100, Tiffin, OH 44883-9356 | |
| (419) 447-7203 | |
| (419) 447-5577 |
| Full Name | Karen Jean Laderach |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 2550 S State Route 100, Tiffin, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295190387 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT.009122 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karen Jean Laderach, OTR/L 1207 Hurd Ave, Findlay, OH 45840-2215 Ph: (219) 242-1161 | Karen Jean Laderach, OTR/L 2550 S State Route 100, Tiffin, OH 44883-9356 Ph: (419) 447-7203 |
News Archive
Since 2004, Claude Knauf (INSERM) and Patrice Cani (UCLouvain) have been collaborating on molecular and cellular mechanisms in order to understand the causes of the development of type 2 diabetes and above all to identify new therapeutic targets.
Listening to the lawyers talking nonstop last week about health care gave me a headache, so I decided to consult one of the nation's top doctors. He offered a real-world diagnosis of what's happening in health care -; and a reminder of how much it's changing, regardless of what the Supreme Court decides about Obamacare. My medical guru is Delos "Toby" Cosgrove, chief executive of Cleveland Clinic, a $6 billion network that's one of the biggest and best providers in the country.
Guided Therapeutics, Inc., developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it has begun human testing of its light-based detection technology for Barrett's Esophagus, a precursor for esophageal cancer. The technology is being jointly developed with Konica Minolta Opto of Japan.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.
› Verified 3 days ago
Kristen A Hoke, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 27 St Lawrence Dr, Suite 104, Tiffin, OH 44883 Phone: 419-455-8600 Fax: 419-455-8613 | |
Mrs. Christina Marrero, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 103 Shepherd Dr, Tiffin, OH 44883 Phone: 419-447-3358 | |
Kristen Nicole Foos, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2550 S State Route 100, Tiffin, OH 44883 Phone: 419-447-7203 | |
Kathryn R Gruenemeyer, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 27 St Lawrence Dr, Suite 104, Tiffin, OH 44883 Phone: 419-447-7203 | |
Dr. Alexis Nicole Caroline, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 45 St Lawrence Dr, Tiffin, OH 44883 Phone: 419-455-7000 | |
Cecilia Taylor, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2550 S State Route 100, Tiffin, OH 44883 Phone: 419-447-7203 |